Valuation Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.10 USD | -0.88% |
|
-2.04% | -2.52% |
Company Valuation: Edwards Lifesciences Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 56,859 | 80,883 | 46,128 | 46,246 | 43,663 | 48,223 | 48,223 | - |
| Change | - | 42.25% | -42.97% | 0.25% | -5.58% | 10.44% | 0% | - |
| Enterprise Value (EV) 1 | 56,271 | 80,616 | 45,956 | 45,198 | 40,285 | 44,752 | 43,484 | 41,865 |
| Change | - | 43.26% | -42.99% | -1.65% | -10.87% | 11.09% | -2.84% | -3.72% |
| P/E ratio | 70.2x | 54.4x | 30.6x | 33.2x | 10.6x | 36.6x | 30.6x | 27.3x |
| PBR | 12.7x | 13.9x | 7.82x | 6.99x | 4.36x | 4.51x | 4.15x | 3.84x |
| PEG | - | 0.7x | 12.14x | -5.79x | 0x | -0.5x | 1.6x | 2.3x |
| Capitalization / Revenue | 13x | 15.5x | 8.57x | 7.7x | 8.03x | 7.99x | 7.29x | 6.64x |
| EV / Revenue | 12.8x | 15.4x | 8.54x | 7.53x | 7.41x | 7.42x | 6.57x | 5.76x |
| EV / EBITDA | 39.4x | 46.6x | 23.7x | 24.1x | 24.1x | 24.6x | 21.3x | 18.3x |
| EV / EBIT | 42.6x | 50.6x | 25.6x | 26.1x | 26.6x | 27x | 23.2x | 19.9x |
| EV / FCF | 86.9x | 57.3x | 47.2x | 47.9x | 139x | 35.2x | 28.7x | 23.4x |
| FCF Yield | 1.15% | 1.74% | 2.12% | 2.09% | 0.72% | 2.84% | 3.48% | 4.27% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 1.3 | 2.38 | 2.44 | 2.3 | 6.97 | 2.268 | 2.712 | 3.041 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 4,386 | 5,232 | 5,382 | 6,005 | 5,440 | 6,032 | 6,617 | 7,263 |
| EBITDA 1 | 1,429 | 1,729 | 1,936 | 1,879 | 1,670 | 1,822 | 2,043 | 2,290 |
| EBIT 1 | 1,322 | 1,594 | 1,796 | 1,734 | 1,514 | 1,660 | 1,873 | 2,100 |
| Net income 1 | 823.4 | 1,503 | 1,522 | 1,402 | 4,175 | 1,317 | 1,583 | 1,775 |
| Net Debt 1 | -588.2 | -267 | -172.7 | -1,048 | -3,378 | -3,471 | -4,739 | -6,358 |
| Reference price 2 | 91.23 | 129.55 | 74.61 | 76.25 | 74.03 | 83.10 | 83.10 | 83.10 |
| Nbr of stocks (in thousands) | 623,248 | 624,334 | 618,260 | 606,500 | 589,800 | 580,300 | 580,300 | - |
| Announcement Date | 27/1/21 | 26/1/22 | 31/1/23 | 6/2/24 | 11/2/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 36.64x | 7.42x | 24.56x | -.--% | 48.22B | ||
| 34.85x | 5.92x | 23.41x | 0.27% | 234B | ||
| 73.1x | 19x | 44.33x | -.--% | 194B | ||
| 45.08x | 7.4x | 24x | 0.52% | 168B | ||
| 45.59x | 7.36x | 24.01x | -.--% | 139B | ||
| 22.43x | 2.63x | 12.84x | 2.17% | 61.18B | ||
| 27.53x | 5.77x | 20.1x | 0.71% | 41.37B | ||
| 18.61x | 2.14x | 12.02x | 0.15% | 38.86B | ||
| 24.7x | 6.53x | 16.89x | 0.93% | 37.8B | ||
| 26.36x | 6.75x | 19.28x | 2.52% | 36.03B | ||
| Average | 35.49x | 7.09x | 22.14x | 0.73% | 99.8B | |
| Weighted average by Cap. | 43.20x | 8.68x | 26.09x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- EW Stock
- Valuation Edwards Lifesciences Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















